Treatment of bone complications in advanced prostate cancer: Rationale for bisphosphonate use and results of a phase III trial with zoledronic acid

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 21, 2002, Pages 19-27

  Saad, Fred ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADVANCED CANCER; ANEMIA; ANOREXIA; BONE METASTASIS; BONE PAIN; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG USE; FATIGUE; FEVER; HUMAN; MORBIDITY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OSTEOLYSIS; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; VOMITING;

BONE NEOPLASMS; BONE RESORPTION; CLINICAL TRIALS; CLINICAL TRIALS, PHASE III; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; PALLIATIVE CARE; PROSTATIC NEOPLASMS;

EID: 0037274882     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.37418     Document Type: Conference Paper

References (61)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
2. International Agency for Research on Cancer: Cancer at all ages-males. Netherlands Cancer Institute. Available at: http: telescan.nki.nl/iarc.html
3. Koeneman KS, Yeung F, Chung LWK: Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39:246-261, 1999
4. Carlin BI, Andriole GL: The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88:2989-2994, 2000 (suppl)
5. Saitoh H, Hida M, Shimbo T, et al: Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer 54:3078-3084, 1984
6. Urwin GH, Percival RC, Harris S, et al: Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 57:721-723, 1985
7. Denis LJ, Griffiths K: Endocrine treatment in prostate cancer. Semin Surg Oncol 18:52-74, 2000
8. Boccardo F: Hormone therapy of prostate cancer: Is there a role for antiandrogen monotherapy? Crit Rev Oncol Hematol 35:121-132, 2000
9. Daniell HW: Osteoporosis after orchiectomy for prostate cancer. J Urol 157:439-444, 1997
10. Coleman RE: Skeletal complications of malignancy. Cancer 80:1588-1594, 1997 (suppl)
11. Mercadante S: Malignant bone pain: pathophysiology and treatment. Pain 69:1-18, 1997
12. Haczynski J, Jakimiuk A: Vertebral fractures: A hidden problem of osteoporosis. Med Sci Monit 7:1108-1117, 2001
13. Eke N: Symptomatic spinal cord involvement in prosrate cancer. Cent Aft J Med 47:49-53, 2001
14. Habermann ET, Lopez RA: Metastatic disease of bone and treatment of pathological fractures. Orthop Clin North Am 20:469-486, 1989
15. Poor G, Atkinson EJ, Lewallen DC, et al: Age-related hip fractures in men: Clinical spectrum and short-term outcomes. Osteoporos Int 5:419-426, 1995
16. Lipton A, Theriault RL, Hortobagyi GN, et al: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebocontrolled trials. Cancer 88:1082-1090, 2000
17. Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377-387, 2001
18. Berenson JR, Lichtenstein A, Porter L, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334:488-493, 1996
19. Berenson JR, Lichtenstein A, Porter L, et al: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593-602, 1998
20. Adami S, Salvagno G, Guarrera G, et al: Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton, J Urol 134:1152-1154, 1985
21. Adami S, Mian M: Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res 116:67-72, 1989
22. Vorreuther R: Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol 72:792-795, 1993
23. Kylmala T, Tammela TL, Lindholm TS, et al: The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann Chir Gynaecol 83:316-319, 1994
24. Cresswell SM, English PJ, Hall RR, et al: Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol 76:360-365, 1995
25. Elomaa I, Kylmala T, Tammela T, et al: Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol 24:159-166, 1992
26. Paterson AH, Powles TJ, Kanis JA, et al: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65, 1993
27. Papapoulos SE, Hamdy NA, van der Pluijm G: Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer 88:3047-3053, 2000 (suppl)
28. Saad F, Gleason D, Small E, et al: Zoledronic acid is effective for the treatment of bone metastases in men with advanced prostate cancer. Presented at the 34th International Consultation on Prostate Cancer, Paris, France, June 21-23, 2002
29. Ernst DS, Tannock IF, Venner PM, et al: A randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study. Proc Am Soc Clin Oncol 21:177a, 2002 (abstr)
30. Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468, 2002
31. Raisz LG: Physiology and pathophysiology of bone remodeling. Clin Chem 45:1353-1358, 1999
32. Goltzman D, Karaplis AC, Kremer R, et al: Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 88:2903-2908, 2000 (suppl)
33. Guise TA, Mundy GR: Cancer and bone. Endocr Rev 19:18-54, 1998
34. Berruti A, Dogliotti L, Bitossi R, et al: Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164:1248-1253, 2000
35. Blomme EAG, Dougherty KM, Pienta KJ, et al: Skeletal metastasis of prostate adenocarcinoma in rats: Morphometric analysis and role of parathyroid hormone-related protein. Prostate 39:187-197, 1999
36. Garnero P, Buchs N, Zekri J, et al: Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82:858-864, 2000
37. Shimazaki J, Higa T, Akimoto S, et al: Clinical course of bone metastasis from prostatic cancer following endocrine therapy: Examination with bone x-ray. Adv Exp Med Biol 324:269-275, 1992
38. Coleman RE, Purohit OP, Black C, et al: Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 10:311-316, 1999
39. Percival RC, Urwin GH, Harris S, et al: Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 13:41-49, 1987
40. Pelger RC, Hamdy NA, Zwinderman AH, et al: Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 22:403-408, 1998
41. Diamond T, Campbell J, Bryant C, et al: The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83:1561-1566, 1998
42. Smith JA Jr: Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 141:85-87, 1989
43. Kylmala T, Taube T, Tammela TL, et al: Concomitant i.v. and oral clodronate in the relief of bone pain - A doubleblind placebo-controlled study in patients with prostate cancer. Br J Cancer 76:939-942, 1997
44. Strang P, Nilsson S, Brandstedt S, et al: The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res 17:4717-4721, 1997
45. Lipton A, Small E, Saad F, et al: The new bisphosphonate, ZOMETA (zoledronic acid) decreases skeletal complications in both lyric and blastic lesions: a comparison to pamidronate. Cancer Invest 20:45-47, 2001 (suppl) (abstr)
46. Djulbegovic B, Wheatley K, Ross J, et al: Bisphosphonates in multiple myeloma (Cochrane Review). The Cochrane Library 3:CD003188, 2002
47. Major P, Cook R: Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints Am J Clin Oncol 25:S10-S18, 2002 (suppl)
48. Andersen PK, Gill RD: Cox's regression model for counting processes: A large sample study. Ann Stat 10:1100-1120, 1982
49. Landis RJ, Heyman ER, Koch GG: Average partial association in three-way contingency tables: A review and discussion of alternative tests. Int Star Rev 46:237-254, 1978
50. Cook RJ, Major P: Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst 93:534-538, 2001
51. Cree M, Soskolne CL, Belseck E, et al: Mortality and institutionalization following hip fracture. J Am Geriatr Soc 48:283-288, 2000
52. Foumeau l, Broos P: Pathologic fractures due to metastatic disease. A retrospective study of 160 surgically treated fractures. Acta Chir Belg 98:255-260, 1998
53. Colyer RA: Surgical stabilization of pathological neoplastic fractures. Curt Probl Cancer 10:117-168, 1986
54. Harrington KD: Orthopedic surgical management of skeletal complications of malignancy. Cancer 80:1614-1627, 1997
55. Zojer N, Keck AV, Pecherstorfer M: Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 21:389-406, 1999
56. Rosen L, Gordon D, Tchekmedyian S, et al: Zoledronic acid significantly reduced the occurrence of skeletal related events (SREs) in patients with osteolytic bone metastases from non-small cell lung cancer (NSCLC) and other solid tumors (OST). Presented at the 3rd International Congress on Prevention and Early Detection of Lung Cancer, Reykjavik, Iceland, August 9-12, 2001 (abstr)
57. Rosen L, Gordon D, Tchekmedyian S, et al: Zoledronic acid (Zol) significantly reduces skeletal-related events (SREs) in patients with bone metastases from solid tumors. Proc Am Soc Clin Oncol 21:295a, 2002 (abstr)
58. Coleman RE, Rosen LS, Gordon D, et al: Zoledronic acid (4 mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90 mg) in patients with breast cancer and bone metastasis. To be presented at the 25th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, December 11-14, 2002 (abstr)
59. Townsend MF, Sanders WH, Northway RO, et al: Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79:545-550, 1997
60. Berruti A, Dogliotti L, Terrone C, et al: Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167:2361-2367, 2002
61. Smith MR, Shasha D, Mansour R, et al. ZOMETA increases bone mineral density in men undergoing androgen deprivation therapy for prostate cancer. Presented at the 3rd North American Symposium: Skeletal Complications of Malignancy, April 25-27, 2002, Bethesda, MD